Volume 2 Issue 3
www.westlandpublishers.com

ISSN: 3066-3822

WestLand Publishers

Digital Journal of Science (DJS)

Short Communication

Dermatological Toxicity of Monoclonal Antibodies in Oncological Diseases

Melisa Hunis, Adrian Hunis*

School of Medicine, Universidad de Buenos Aires, Argentina

***Corresponding Author:**

Adrián Pablo Huñis, School of Medicine, Universidad de Buenos Aires, Argentina.

Received Date: 11 March, 2025 ; **Published Date:** 31 March, 2025

Keywords:

Artificial Intelligence; Higher Education; Educational Innovation; Educational Integrity

Citation:

Melisa H, Adrian H (2024) Dermatological Toxicity of Monoclonal Antibodies in Oncological Diseases. Digital J Sci 2(3): 122.

Abstract

Monoclonal antibodies (mAbs) have revolutionized cancer treatment by offering targeted therapeutic options. However, their use is associated with various adverse effects, including dermatological toxicity. This article provides a comprehensive review of the dermatological toxicities linked to mAbs in oncology patients, detailing the mechanisms, frequency, and management strategies for these skin-related side effects.

Introduction

The introduction of monoclonal antibodies has significantly advanced cancer therapy by providing a targeted approach to treatment [1]. Unlike traditional chemotherapy, which can affect both cancerous and healthy cells, mAbs are engineered to specifically target antigens on cancer cells, thereby reducing collateral damage. Despite their targeted nature, mAbs are not without side effects, with dermatological toxicities being among the most common [2]. Understanding these toxicities is essential for optimizing patient outcomes and improving quality of life during treatment.

Monoclonal Antibodies Used in Cancer

Monoclonal antibodies are employed in the treatment of various cancers, each targeting specific antigens associated with particular cancer types. For instance, trastuzumab targets the HER2 receptor in breast cancer, cetuximab targets the Epidermal Growth Factor Receptor (EGFR) in colorectal cancer, and rituximab targets the CD20 antigen in non-Hodgkin lymphomas [3]. The specificity of these antibodies allows for targeted therapy, reducing off-target effects but still presenting unique challenges in terms of toxicity.

Pharmacological Mechanism of Action

The mechanism of action of monoclonal antibodies involves binding to specific antigens on the surface of cancer cells, leading to cell death through several pathways:

1. **Antibody-Dependent Cellular Cytotoxicity (ADCC):** Once bound to the target antigen, mAbs can recruit immune cells, such as natural killer cells, to destroy the cancer cell [4].

2. **Complement-Dependent Cytotoxicity (CDC):** The binding of mAbs can activate the complement system, leading to the formation of a membrane attack complex that lyses the cancer cell [5].

3. **Inhibition of Cell Signaling Pathways:** mAbs can block signaling pathways essential for cancer cell proliferation and survival, thereby inhibiting tumor growth [6].

Table 1: This table provides an overview of some of the most commonly used mAbs in oncology practice, along with their molecular targets and the indications for which they are approved.

Monoclonal Antibody	Target Antigen	Indications
Trastuzumab	HER2	Breast cancer, Gastric cancer
Rituximab	CD20	Non-Hodgkin lymphoma, CLL
Cetuximab	EGFR	Colorectal cancer, Head and neck cancer
Bevacizumab	VEGF	Colorectal cancer, Lung cancer, Renal cell carcinoma
Pembrolizumab	PD-1	Melanoma, Non-small cell lung cancer, Head and neck cancer
Nivolumab	PD-1	Melanoma, Renal cell carcinoma, Non-small cell lung cancer
Ipilimumab	CTLA-4	Melanoma
Atezolizumab	PD-L1	Non-small cell lung cancer, Urothelial carcinoma
Daratumumab	CD38	Multiple myeloma
Brentuximab vedotin	CD30	Hodgkin lymphoma, Anaplastic large cell lymphoma



Figure 1: Patient treated with nivolumab, courtesy of Dr. Adrian Hunis

General Toxicity

While mAbs are generally considered safer than traditional chemotherapy, they are not devoid of side effects. Common toxicities include infusion-related reactions, such as fever and chills, hematological effects like neutropenia, and organ-specific toxicities affecting the liver, lungs, or heart [7]. The severity of these side effects can vary based on the specific mAb and the patient's individual response.

Dermatological Toxicity

Dermatological toxicity is a common adverse effect associated with mAbs, presenting as a variety of skin lesions. These can include:

- **Rash:** Often papulopustular, resembling acne, and commonly affecting the face, scalp, and upper body [8].
- **Pruritus:** Intense itching that can accompany or occur independently of a rash [9].
- Abnormal dryness of the skin, which can lead to cracking and increased susceptibility to infection [10].
- **Paronychia:** Inflammation of the nail folds, which can be painful and lead to secondary infections [11].



Figure 2: Patient treated with nivolumab, courtesy of Dr. Adrian Hunis

Frequency of Dermatological Toxicity

The incidence of dermatological toxicity varies widely among different mAbs and cancer types. For example, up to 80% of patients receiving EGFR inhibitors like cetuximab may experience some form of skin toxicity [12]. The frequency and severity of these reactions can also depend on patient-specific factors, including genetic predispositions and concurrent medications [13].

Correlation Between Toxicity and Treatment Response

Interestingly, there is a growing body of evidence suggesting that the presence of dermatological toxicity may correlate with better treatment outcomes. This phenomenon is particularly noted in patients receiving EGFR inhibitors, where the development of a rash has been associated with improved survival rates [14]. The underlying mechanism is thought to involve an enhanced immune response, indicating that the skin reactions may serve as a biomarker for treatment efficacy [15].

Management of Dermatological Toxicity

Effective management of dermatological toxicity is essential to maintain patient quality of life and adherence to cancer therapy. Strategies include:

- **Topical Treatments:** Corticosteroids and emollients can help alleviate inflammation and dryness [16].
- **Systemic Treatments:** Oral antihistamines and antibiotics may be necessary for severe pruritus or secondary infections [17].
- **Dose Modification:** In cases of severe toxicity, adjusting the dosage of the mAb or temporarily discontinuing treatment may be required [18].
- **Patient Education:** Educating patients about potential skin reactions and encouraging early reporting can facilitate prompt management [19].

Conclusion

Monoclonal antibodies represent a significant advancement in cancer therapy, offering targeted treatment options with improved efficacy. However, their use is accompanied by dermatological toxicities that can impact patient quality of life. Understanding the mechanisms, frequency, and management of these skin-related side effects is crucial for optimizing treatment outcomes and ensuring patient adherence to therapy.

Conflict of Interest

The authors declare no conflicts of interest.

Financial Support and Sponsorship

No financial support or sponsorship was received.

References

1. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 9(7): 463-475.
2. Eisen DB (2010) Surgeon's garb and infection control: What's the evidence?. Journal of the American Academy of Dermatology 64(5): 60.e1-960.e20.
3. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nature Reviews Cancer 12(4): 278-287.
4. Weiner GJ (2015) Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer 15(6): 361-370.
5. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, et al. (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine 375(19): 1856-1867.
6. Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, et al. (2015) Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol) 26(6): 323-332.
7. Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology 23(22): 5235-5246.
8. Lynch TJ, Kim ES, Eaby B, Garey J, West DP, et al. (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. The Oncologist 12(5): 610-621.
9. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer 6(10): 803-812.
10. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology 16(9): 1425-1433.

11. Robert C, Schachter J, Long GV, Arance A, Grob JJ, et al. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine 372(26): 2521-2532.

12. Brahmer JR, Tykodi S, Chow LQM, Wen-Jen H, Topalian SL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine 366(26): 2455-2465.

13. Herbst RS, Baas P, Dong-Wan K, Felip E, Pérez-Gracia JL, et al. (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387(10027): 1540-1550.

14. Topalian SL, Hodi SF, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 366(26): 2443-2454.

15. Sexton-Oates, MacGregor D, Dodgshun A, Saffery R (2015) The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis. Annals of Oncology 26: 1314-1324.

16. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, et al. (2009) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 23(34): 8646-8654.

17. Sibaud V (2016) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 17(3): 223-237.

18. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al. (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17): 1714-1768.

19. Lacouture ME, Sibaud V, Gerber PA, van den HC, Fernández-Peñas P, et al. (2021) Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol 32(2): 230-238.